Volume 23, Number 4—April 2017
Zika Virus Seroprevalence, French Polynesia, 2014–2015
|Sampled population, time of sampling, location of sampling||Median age (range), y||No. symptomatic/no. positive (% [95% CI])||No. asymptomatic/no. positive (% [95% CI])||Total no. seropositive/total no. tested (% [95% CI])|
|Society Islands||47 (13–77)||8/18 (44 [26–69])||10/18 (56 [33–79])||18/49 (37 [26–47])|
|Tuamotu Islands||39 (7–86)||12/22 (55 [34–75])||10/22 (45 [25–66])||22/49 (45 [38–52])|
|Marquesas Islands||45 (10–82)||16/28 (57 [39–75])||12/28 (43 [24–61])||28/49 (57 [47–68])|
|Austral–Gambier Islands||38 (7–84)||19/29 (66 [48–83])||10/29 (34 [17–52])||29/49 (59 [39–80])|
||55/97 (57 [47–67])
||42/97 (43 [33–53])
||97/196 (49 [42–57])
||73/154 (47 [40–55])
||81/154 (53 [45-61])
||154/700 (22 [16–28])
|Society Islands||11 (6–16)||221/312 (71 [66–76[)||91/312 (29 [24–34])||312/476 (66 [60–71])|
*CIs were calculated taking into account the cluster sampling design (9) and using the Fisher exact test.
- Musso D, Gubler DJ. Zika Virus. Clin Microbiol Rev. 2016;29:487–524.
- Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387:1531–9.
- Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387:2125–32.
- Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43.
- Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry A-L, Mallet H-P, et al. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis. 2014;20:1085–6.
- Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect. 2014;20:O595–6.
- Mallet HP, Vial AL, Musso D. Bilan de l’épidémie à virus Zika survenue en Polynésie française entre octobre 2013 et mars 2014. De la description de l’épidémie aux connaissances acquises après l’évènement. Bulletin épidémiologique hebdomadaire. 2016;20–21:367–73.
- Aubry M, Finke J, Teissier A, Roche C, Broult J, Paulous S, et al. Seroprevalence of arboviruses among blood donors in French Polynesia, 2011-2013. Int J Infect Dis. 2015;41:11–2.
- Spiegel A, Moulia-Pelat J, Daumerie D, Merlin M, Baudon D. Le sondage en grappe type OMS : méthodes pratiques en épidémiologie descriptive. Med Afr Noire. 1989;36:740–5.
- Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill. 2014;19:2pii=0761.
- Chungue E, Marché G, Plichart R, Boutin JP, Roux J. Comparison of immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA) and haemagglutination inhibition (HI) test for the detection of dengue antibodies. Prevalence of dengue IgG-ELISA antibodies in Tahiti. Trans R Soc Trop Med Hyg. 1989;83:708–11.
- Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17:1102–8.
- Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113:7852–7.
- Kucharski AJ, Funk S, Eggo RM, Mallet H-P, Edmunds WJ, Nilles EJ. Transmission dynamics of Zika virus in island populations: a modelling analysis of the 2013–14 French Polynesia outbreak. PLoS Negl Trop Dis. 2016;10:e0004726.
- Johansson MA, Hombach J, Cummings DA. Models of the impact of dengue vaccines: a review of current research and potential approaches. Vaccine. 2011;29:5860–8.
Page created: March 16, 2017
Page updated: March 16, 2017
Page reviewed: March 16, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.